» Articles » PMID: 33168847

Platelet PD-L1 Suppresses Anti-cancer Immune Cell Activity in PD-L1 Negative Tumors

Overview
Journal Sci Rep
Specialty Science
Date 2020 Nov 10
PMID 33168847
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Strategies that interfere with the binding of the receptor programmed cell death protein-1 (PD-1) to programmed death ligand-1 (PD-L1) have shown marked efficacy against many advanced cancers, including those that are negative for PD-L1. Precisely why patients with PD-L1 negative tumors respond to PD-1/PD-L1 checkpoint inhibition remains unclear. Here, we show that platelet-derived PD-L1 regulates the growth of PD-L1 negative tumors and that interference with platelet binding to PD-L1 negative cancer cells promotes T cell-induced cancer cytotoxicity. These results suggest that the successful outcomes of PD-L1 based therapies in patients with PD-L1 negative tumors may be explained, in part, by the presence of intra-tumoral platelets. Altogether, our findings demonstrate the impact of non-cancer/non-immune cell sources of PD-L1 in the tumor microenvironment in the promotion of cancer cell immune evasion. Our study also provides a compelling rationale for future testing of PD-L1 checkpoint inhibitor therapies in combination with antiplatelet agents, in patients with PD-L1 negative tumors.

Citing Articles

Enhanced thrombopoiesis supplies PD-L1 to circulating immune cells via the generation of PD-L1-expressing platelets in patients with lung cancer.

Lee S, Jeong S, Kim Y, Noh J, Rho K, Kim H J Immunother Cancer. 2025; 13(2).

PMID: 40010769 PMC: 11865743. DOI: 10.1136/jitc-2024-010193.


Prognostic value of immuno-inflammatory biomarkers in esophageal squamous cell carcinoma patients receiving immunotherapy combined with chemoradiotherapy and its association with immuno-genomic landscape.

Cheng X, Meng F, Wang R, Liu S, Li Q, Chen B BMC Cancer. 2024; 24(1):1518.

PMID: 39696104 PMC: 11657211. DOI: 10.1186/s12885-024-13298-z.


The impact of platelets on the metastatic potential of tumour cells.

Raskov H, Orhan A, Agerbaek M, Gogenur I Heliyon. 2024; 10(14):e34361.

PMID: 39114075 PMC: 11305202. DOI: 10.1016/j.heliyon.2024.e34361.


Potential Role of Circulating PD-L1 Leukocytes as a Predictor of Response to Anti-PD-(L)1 Therapy in NSCLC Patients.

Anguera G, Mulet M, Zamora C, Osuna-Gomez R, Barba A, Sullivan I Biomedicines. 2024; 12(5).

PMID: 38790920 PMC: 11117542. DOI: 10.3390/biomedicines12050958.


The localization, origin, and impact of platelets in the tumor microenvironment are tumor type-dependent.

Le Chapelain O, Jadoui S, Gros A, Barbaria S, Benmeziane K, Ollivier V J Exp Clin Cancer Res. 2024; 43(1):84.

PMID: 38493157 PMC: 10944607. DOI: 10.1186/s13046-024-03001-2.


References
1.
Karpatkin S, Pearlstein E, Ambrogio C, Coller B . Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J Clin Invest. 1988; 81(4):1012-9. PMC: 329625. DOI: 10.1172/JCI113411. View

2.
Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

3.
Sharma P, Allison J . Dissecting the mechanisms of immune checkpoint therapy. Nat Rev Immunol. 2020; 20(2):75-76. DOI: 10.1038/s41577-020-0275-8. View

4.
Lin H, Wei S, Hurt E, Green M, Zhao L, Vatan L . Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. J Clin Invest. 2018; 128(4):1708. PMC: 5873851. DOI: 10.1172/JCI120803. View

5.
Yuan L, Liu X . Platelets are associated with xenograft tumor growth and the clinical malignancy of ovarian cancer through an angiogenesis-dependent mechanism. Mol Med Rep. 2014; 11(4):2449-58. PMC: 4337475. DOI: 10.3892/mmr.2014.3082. View